CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Incyte Corporation
Amgen
Dren Bio
AVM Biotechnology Inc
BeOne Medicines
Lyell Immunopharma, Inc.
BeOne Medicines
Janssen Research & Development, LLC
Innate Pharma
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Genmab
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
AstraZeneca
Nurix Therapeutics, Inc.
Beijing Biotech
Gilead Sciences
Merck Sharp & Dohme LLC
Genmab
Autolus Limited
Genmab
Genmab
Hoffmann-La Roche
Bristol-Myers Squibb
AstraZeneca
Hoffmann-La Roche
Novartis
Artiva Biotherapeutics, Inc.
CRISPR Therapeutics
AstraZeneca
AvenCell Therapeutics, Inc.
Dizal Pharmaceuticals
Debiopharm International SA
Vironexis Biotherapeutics Inc.
Amgen
Pfizer
AstraZeneca
Dizal Pharmaceuticals
Acerta Pharma BV
Sumitomo Pharma America, Inc.
Taiho Oncology, Inc.
Hoffmann-La Roche
Syndax Pharmaceuticals
AstraZeneca
Guangzhou Bio-gene Technology Co., Ltd
Merck Sharp & Dohme LLC
Autolus Limited
Sellas Life Sciences Group